Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

China Medical System Licenses Teikoku’s Lidoderm for Postherpetic Neuralgia in China

Fineline Cube Feb 13, 2026
Company Deals

Salubris Pharma Files Hong Kong IPO for Secondary Listing to Expand Cardiorenal Metabolic Franchise

Fineline Cube Feb 13, 2026
Company Deals

Immunofoco Bio Files Hong Kong IPO for Solid Tumor CAR-T Pipeline

Fineline Cube Feb 13, 2026
Company Deals

Ribo Life Science Licenses $4.4 Billion MASH siRNA Portfolio to Madrigal Pharmaceuticals

Fineline Cube Feb 12, 2026
Company Deals

Novartis Secures Long-Term Actinium-225 Supply from Niowave for Radioligand Therapy Expansion

Fineline Cube Feb 12, 2026
Policy / Regulatory

FDA Cracks Down on Compounded GLP-1 APIs; Novo Nordisk Sues Hims & Hers for Patent Infringement

Fineline Cube Feb 11, 2026
Company Drug

Amgen’s UPLIZNA Wins European Approval for Generalized Myasthenia Gravis

Fineline Cube Feb 13, 2026
Company Drug

Innovent Biologics Initiates Phase 3 HeriCare-Breast01 Study for IBI354 in HER2+ Breast Cancer

Fineline Cube Feb 13, 2026
Company Deals

ImmuneOnco Receives $10M Milestone Payment from Instil Bio for IMM2510/IMM27M Collaboration

Fineline Cube Jul 31, 2025

China-based ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) announced today that it has received a...

Company Deals

Luoxin Pharmaceutical Transfers Equity Stake to Shanghai Pharma for RMB 415 Million

Fineline Cube Jul 31, 2025

China-based Luoxin Pharmaceutical Group Co., Ltd. (SHE: 002793) announced that its subsidiary, Shandong Luoxin Pharmaceutical...

Company Deals

Sino Biopharmaceutical on Track to Receive $300M Milestone Payment for PD-1/VEGF Antibody Deal

Fineline Cube Jul 31, 2025

China-based Sino Biopharmaceutical Ltd (HKG: 1177) has announced that the out-licensing collaboration between its subsidiary...

Company Deals

Walvax Expands Rights to Notitia’s Gut Microbiota Therapy in Greater China

Fineline Cube Jul 31, 2025

Walvax Biotechnology Co., Ltd (SHE: 300142), a Chinese biopharmaceutical company, has announced that an amendment...

Company Drug

Sanofi’s SAR446523 Gains FDA Orphan Drug Status for Relapsed or Refractory Multiple Myeloma

Fineline Cube Jul 31, 2025

French pharmaceutical major Sanofi (NASDAQ: SNY) reported that the U.S. Food and Drug Administration (FDA)...

Company Deals

Sandoz to Acquire Evotec’s Biologics Unit for $300 Million Expansion

Fineline Cube Jul 31, 2025

Switzerland-headquartered Sandoz (SWX: SDZ) announced that it has signed a non-binding term sheet with Germany’s...

Company Drug

Zhaoke Ophthalmology’s Melphalan Granted FDA Orphan Drug Designation for Pediatric Retinoblastoma

Fineline Cube Jul 31, 2025

China-based Zhaoke Ophthalmology Ltd (HKG: 6622), a leader in ophthalmic solutions, today announced that its...

Company Deals

Zhaoke Ophthalmology Partners with French FAREVA for Strategic Expansion

Fineline Cube Jul 31, 2025

China-based Zhaoke Ophthalmology (HKG: 6622) announced the signing of a Memorandum of Agreement (MOA) with...

Company Deals

Lee’s Pharma Partners with Shaohe Biotech to Translate Probiotics into Public Health Solutions

Fineline Cube Jul 31, 2025

China-based Lee’s Pharmaceutical Holdings Ltd. (HKG: 0950) announced on July 28, 2025, that it has...

Company

GSK Reports 6% Sales Growth in Q2 2025, Driven by Specialty Medicine and Vaccines

Fineline Cube Jul 31, 2025

UK-based GlaxoSmithKline (GSK; NYSE: GSK) released its Q2 and H1 2025 financial results. Q2 sales...

Company Deals

CSPC Signs Exclusive Licensing Deal with Madrigal for GLP-1 Agonist SYH2086

Fineline Cube Jul 31, 2025

China-based CSPC Pharmaceutical Group Limited (HKG: 1093) announced today that it has entered into an...

Company Drug

HRAIN Biotech’s HICARA Approved by NMPA for Relapsed/Refractory LBCL

Fineline Cube Jul 31, 2025

The National Medical Products Administration (NMPA) officially approved the New Drug Application (NDA) for lenecabtagene...

Company Drug

Eli Lilly’s Jaypirca Achieves Primary Endpoint in Phase III BRUIN CLL-314 Trial

Fineline Cube Jul 30, 2025

US pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) announced on July 29, 2025, that...

Company Drug

Shanghai Pharmaceuticals’ B019 Injection Approved for SLE Clinical Trials

Fineline Cube Jul 30, 2025

Shanghai Pharmaceuticals Holding Co., Ltd’s (SPH, HKG: 2607, SHA: 601607) announced that it has received...

Company Drug

Bayer’s Sevabertinib Granted Priority Review by China’s NMPA for NSCLC Treatment

Fineline Cube Jul 30, 2025

German pharmaceutical giant Bayer AG (ETR: BAYN) announced on July 28, 2025, that the marketing...

Company Deals

LTZ Therapeutics and Eli Lilly Partner to Develop Myeloid Engager Therapeutics

Fineline Cube Jul 30, 2025

LTZ Therapeutics and Eli Lilly (NYSE: LLY) announced a significant strategic collaboration on July 29,...

Company Drug

Huadong Medicine Receives NMPA Approval for Phase III Trial of Psoriasis Cream MC2-01

Fineline Cube Jul 30, 2025

China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that it has received approval from the...

Others

China Medical System’s ZUNVEYL NDA Accepted by China’s NMPA for Alzheimer’s Treatment

Fineline Cube Jul 30, 2025

China Medical System Holdings Ltd (CMS; HKG: 0867, SGX: 8A8) announced on July 28, 2025,...

Company

MSD’s Q2 Earnings Hit by Gardasil Sales Decline, Keytruda Growth Slows

Fineline Cube Jul 30, 2025

US-based Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK) announced its Q2 2025 financial results,...

Company

Novo Nordisk Shares Plummet 20% as Obesity Drug Competition Intensifies and Full-Year Guidance Lowered

Fineline Cube Jul 30, 2025

Shares of Denmark-based biopharma giant Novo Nordisk A/S (NYSE: NVO) dipped over 20% during trading...

Posts pagination

1 … 79 80 81 … 624

Recent updates

  • Novocure’s Optune Pax Wins FDA Approval for Pancreatic Cancer; Zai Lab China Rights in Play
  • China Medical System Licenses Teikoku’s Lidoderm for Postherpetic Neuralgia in China
  • Organon Reports 2025 Revenue Decline to $6.2 Billion; JADA Sale and Portfolio Pressures Weigh
  • Salubris Pharma Files Hong Kong IPO for Secondary Listing to Expand Cardiorenal Metabolic Franchise
  • Sanofi Appoints Belén Garijo as New CEO to Drive R&D Innovation and Productivity
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Medical Device

Novocure’s Optune Pax Wins FDA Approval for Pancreatic Cancer; Zai Lab China Rights in Play

Company Deals

China Medical System Licenses Teikoku’s Lidoderm for Postherpetic Neuralgia in China

Company

Organon Reports 2025 Revenue Decline to $6.2 Billion; JADA Sale and Portfolio Pressures Weigh

Company Deals

Salubris Pharma Files Hong Kong IPO for Secondary Listing to Expand Cardiorenal Metabolic Franchise

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.